Behavioral activation significantly reduced suicidal ideation in women with perinatal depression, showing effectiveness whether delivered in-person or remotely by specialists and non-specialists.
Treatment with zuranolone, a novel oral antidepressant for postpartum depression, raises important questions for breastfeeding individuals. While recent studies show minimal transfer into breast milk, we do not yet have enough information to recommend breastfeeding while taking zuranolone.
New documentary illuminates the faces and voices of postpartum depression across America.
In a recent study from Mass General Hospital, researchers examined whether information included in the medical record at the time of discharge after delivery could help us to identify individuals at increased risk for postpartum depression.
By implementing trauma-informed strategies, healthcare providers can help create a safe and supportive environment for sexual trauma survivors during pregnancy, labor, and delivery.
The Healthy Mother - Healthy Baby intervention delivered by non-specialists cuts postpartum depression risk by 81% through anxiety-focused care.
Blood levels of neuroactive steroids during the third trimester of pregnancy may predict increased risk of postpartum depression, offering possibility for early intervention.
Individuals with postpartum depression are being recruited for a clinical trial of a novel psychedelic compound, RE104.
Further studies are needed to determine whether ketamine and esketamine are effective for the treatment of postpartum depression.
MamaLift Plus is a prescription-only digital therapeutic intervention for the treatment of mild to moderate postpartum depression using several different neurobehavioral interventions.
